Introduction

Cytosor 100 mg (Cytarabine) Injection is a potent antimetabolite chemotherapy agent designed for the treatment of acute leukemias and leukemic meningitis. Manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Onco Solution, Cytosor 100 mg (Cytarabine) Injection inhibits DNA synthesis, effectively targeting rapidly dividing cancer cells. With its proven efficacy and manageable safety profile, Cytosor 100 mg (Cytarabine) Injection is a cornerstone in modern oncology protocols.

Indications

Cytosor 100 mg (Cytarabine) Injection is indicated for:

1. Leukemic Meningitis: Intrathecal administration for CNS involvement.
2. Acute Leukemias: Induction and maintenance of remission in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Pharmacology

Cytosor 100 mg (Cytarabine) Injection exerts its cytotoxic effects by:

• Inhibiting DNA polymerase, preventing DNA synthesis and replication.
• Incorporating into DNA, leading to chain termination and cell death.
• Exhibiting antiviral and immunosuppressant activity.

Pharmacokinetics:

• Distribution: Rapidly distributed into tissues and cerebrospinal fluid (CSF).
• Metabolism: Primarily hepatic, converted to active and inactive metabolites.
• Excretion: Renal (70–80%) and biliary (10–20%).

Dosage & Administration

Cytosor 100 mg (Cytarabine) Injection is administered via intrathecal or intravenous routes under the supervision of an oncology specialist.

Recommended Dosage:

• Leukemic Meningitis (Intrathecal):
  • 5–75 mg/m² or 30–100 mg once every 2–7 days for 4–5 days.
  • For lymphomatous meningitis: 50 mg every 2 weeks for 5 doses, then every 4 weeks for 5 doses.
• Acute Leukemias (IV):
  • Monotherapy: 200 mg/m² daily by continuous IV infusion for 5 days, repeated every 2 weeks.
  • Combination Therapy: 100 mg/m² twice daily by rapid IV injection or 100 mg/m² daily by continuous IV infusion for 7 days.
  • Maintenance Therapy: 1–1.5 mg/kg once or twice weekly via IV or SC.

Precautions:

• Monitor renal and hepatic function regularly.
• Avoid intrathecal administration in patients with active meningeal infections.

Drug Interactions

• 5-Fluorocytosine: Reduced efficacy.
• Digoxin/Gentamicin: Reduced therapeutic effects.
• Other Cytotoxic Agents: Increased risk of neurotoxicity (intrathecal use).

Contraindications

• Active meningeal infection.
• Hypersensitivity to cytarabine or any component of the formulation.

Side Effects

Common Adverse Reactions:

• Hematologic: Thrombocytopenia, leukopenia, anemia.
• Gastrointestinal: Nausea, vomiting, diarrhea, anorexia.
• Neurologic: Headache, confusion, weakness.
• Dermatologic: Rash, oral/anal inflammation.

Serious Risks:

• Severe myelosuppression.
• Hepatic dysfunction.
• Neurotoxicity (intrathecal use).

Pregnancy & Lactation

• Pregnancy Category D: Cytosor 100 mg (Cytarabine) Injection may cause fetal harm. Use only if benefits outweigh risks.
• Lactation: Discontinue breastfeeding during treatment and for 1 week after the final dose.

Precautions & Warnings

• Monitor blood counts, liver function, and renal function regularly.
• Use with caution in patients with pre-existing bone marrow suppression.
• Avoid extravasation during administration to prevent tissue necrosis.

Overdose Management

No specific antidote exists. Provide supportive care, including:

• Blood or platelet transfusions.
• Antibiotics for infections.
• Maintenance of vital functions.

Reconstitution & Storage

• Reconstitution:
  • IV: Dilute with bacteriostatic water for injection and further dilute in 250–1000 mL of 0.9% NaCl or 5% dextrose.
  • Intrathecal: Dilute with preservative-free 0.9% NaCl or Elliot’s B solution.
• Storage:
  • IV/SC: Store at 15–25°C.
  • Intrathecal: Store at 2–8°C.
  • Protect from light and avoid freezing.

Manufacturing Excellence

Cytosor 100 mg (Cytarabine) Injection is manufactured by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified company with over 30 years of expertise in oncology therapeutics. Their state-of-the-art facilities ensure:

• Rigorous quality control.
• Compliance with international standards.

Global Supply Network

Onco Solution, the global supplier of Cytosor 100 mg (Cytarabine) Injection, guarantees:

• Reliable, temperature-controlled logistics.
• Compliance with global regulatory requirements.

Clinical Value Proposition

Cytosor 100 mg (Cytarabine) Injection offers:

• Proven efficacy in leukemia and leukemic meningitis.
• Targeted DNA synthesis inhibition.
• Flexible administration routes (IV and intrathecal).

Conclusion

Cytosor 100 mg (Cytarabine) Injection is a vital therapeutic option for leukemia and leukemic meningitis, combining clinical efficacy with a manageable safety profile. Backed by Eskayef Pharmaceuticals Ltd.’s manufacturing excellence and Onco Solution’s global distribution network, Cytosor 100 mg (Cytarabine) Injection ensures reliable access to life-saving oncology care.